Singular and CSIRO enter into collaboration for medical 3D printing
Medical technology company Singular Health has partnered with innovative Australian scientific research agency CSIRO on a project to develop an artificial intelligence-based tool to automatically design replacement ‘cranial implants’ for 3D printing. The company has also entered into a collaboration with Osteopore, listed on ASX, to validate the results of the project. Osteopore uses specialized tissue science and its proprietary 3D printing technology to manufacture regenerative implants.
Singular’s collaboration with CSIRO is part of the research organization’s “Kick-Start Program”. As part of the research initiative, CSIRO provides matching funding to companies that wish to access its expertise to research innovative products and processes.
Singular says he has now received CSIRO funding to the tune of $ 50,000 for a research program seeking to use artificial intelligence to automatically generate cranial implants for craniotomies.
Singular’s technology uses artificial intelligence to analyze the unique shape of a patient’s skull from CT scans before creating a cranial implant model that can be 3D printed.
The artificial intelligence used in the Kick-Start research should be integrated into the company’s “Surgical Planning” software for editing and revision before 3D printing of the implants.
Singular has also entered into a Memorandum of Understanding, or “MoU” with Osteopore, in which the results of the research project will be validated using a dataset provided by Osteopore.
As part of the MoU, a comparative study to test the accuracy and potential time savings of automated generation of cranial implant designs will also be undertaken. The study will compare the design processes of existing cranial implants with the new designs developed in the research project.
Singular’s “3Dicom Surgical” software platform will be used to develop, test and market the fully automated cranial implant tool. Singular will also bring its expertise in software development to the collaboration with Osteopore.
This project marks an exciting step for Singular Health as it highlights our expertise in Artificial Intelligence in the design of patient-specific implants. Too often, advances in medical technology are made without input from peers to focus on business priorities. Working with Osteopore ensures that our work and results will be objectively compared to existing techniques and paves the way for future collaborations and commercialization opportunities.
Osteopore CEO Khoon Seng Goh added:
“As a leader in regenerative medicine, Osteopore collaborates with a range of technologies that improve the effectiveness of our regenerative implants. This win-win formula accelerates the commercialization of future technologies so that surgeons have new solutions for their treatment strategy and patients can be treated early to make the most of their bodies’ healing capacity.
Singular believes the collaboration with Osteopore could also provide future marketing opportunities for the duo.
Osteopore uses an advanced “bioabsorbable” 3D printed network that uses 3D printing to produce medical implants with complex shapes, such as the shape of a skull. The medical implants generated also allow bone reconstruction and restoration.
According to Singular, Osteopore seeks to tap a global market made up of around 1.1 million cranial procedures each year.
Collaborations with CSIRO and Osteopore seem to bode well for Singular as it seeks to advance its innovative technology and solidify its place in the lucrative medical imaging market.
Is Your ASX Listed Company Doing Something Interesting? Contact: [email protected]